Drug Trial Radar · NCT05043922
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
93
Actual
Start
Oct 11, 2021
Primary completion
Jul 31, 2024
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation, who received prior systemic anti-tumor treatment.
Conditions
- Ovarian Cancer
- Recurrent Cancer
Interventions
CYH33Drug
a Selective PI3Kα Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tumor ORR in patients with PIK3CA hotspot mutations.Time frame: through study completion, an average of 1 year
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
Chinese PLA General Hospital
Beijing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
The Southwest Hospital of AMU
Chongqing, China
Sun Yat-sen University Cancer Center
Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University
Guangdong, China
The First Affiliated Hospital of Hainan Medical College
Haikou, China
The Third People's Hospital of Hainan Province
Hainan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Hubei Cancer Hospital
Hubei, China
Hunan Cancer Hospital
Hunan, China
Qilu Hospital of Shandong University
Jinan, China
Jiangsu Province Hospital
Nanjing, China
The People's Hospital Of Guangxi Zhuang Autonomous Region
Nanning, China
Qingdao Central Hospital
Qingdao, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
Shanghai First Maternity and Infant Hospital
Shanghai, China
Xiaohua wu
Shanghai, China
West China Second University Hospital, Sichuan University
Sichuan, China
Tianjin Medical University General Hospital
Tianjin, China
Zhongnan Hospital of Wuhan University
Wuhan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Zhejiang, China
Shikoku Cancer Center
Matsuyama, Japan
Nagoya University Hospital
Nagoya, Japan
Niigata University Medical & Dental Hospital
Niigata, Japan
Okayama University Hospital
Okayama, Japan
Hokkaido University Hospital
Sapporo, Japan
Tohoku University Hospital
Sendai, Japan
Kurume University Hospital
Kurume, Fukuoka, Japan
Osaka University Hospital
Suita, Osaka, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
Jikei University Hospital
Minato-Ku, Tokyo, Japan
Keio University Hospital
Shinjuku-Ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.